Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

Last year, sales of obesity treatments surpassed Keytruda, the immune anticancer drug that had long held the top sales ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...

One day after a double-pronged loss in prostate and lung cancer, Merck & Co.’s immuno-oncology superstar Keytruda is bouncing back. In the phase 3 Keynote-671 study, Keytruda hit one of two primary ...

BioInvent International has reported encouraging interim Phase 2a results showing that combining its BI-1808 antibody with ...

Pembrolizumab (Keytruda) elicited significantly better outcomes compared with ipilimumab (Yervoy) in a randomized phase 3 trial of patients with advanced melanoma. Keytruda (pembrolizumab) elicited ...